Bone disease in HIV infection: A practical review and recommendations for HIV care providers

Clinical Infectious Diseases

Volumn 51, Issue 8, 2010, Pages 937-946

  McComsey, Grace A ^a   Tebas, Pablo ^b   Shane, Elizabeth ^c   Yin, Michael T ^c   Overton, E Turner ^d   Huang, Jeannie S ^e   Aldrovandi, Grace M ^f   Cardoso, Sandra W ^h   Santana, Jorge L ⁱ   Brown, Todd T ^g  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c College of Physicians and Surgeons ^*  (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f CHILDREN S HOSPITAL LOS ANGELES   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h Funda??o Oswaldo Cruz   (Brazil)

ⁱ UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTIRETROVIRUS AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; GLITAZONE DERIVATIVE; GLUCOCORTICOID; IBANDRONIC ACID; METHADONE; OPIATE; PROTON PUMP INHIBITOR; RISEDRONIC ACID; TENOFOVIR; THYROXINE; ZOLEDRONIC ACID;

ADRENAL INSUFFICIENCY; BONE DENSITY; CALCIUM DEFICIENCY; CHRONIC KIDNEY DISEASE; DEPRESSION; DISEASE ASSOCIATION; DRUG MONITORING; DYSPEPSIA; EARLY MENOPAUSE; EMPHYSEMA; ESOPHAGUS CANCER; ESOPHAGUS DISEASE; FRACTURE; FRAGILITY FRACTURE; HEALTH CARE PERSONNEL; HEART ATRIUM FIBRILLATION; HEMOPHILIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIP FRACTURE; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMOBILIZATION; INFECTION; JAW OSTEONECROSIS; MALABSORPTION; METABOLIC ACIDOSIS; OLIGOMENORRHEA; OSTEOMALACIA; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TESTOSTERONE BLOOD LEVEL; TOBACCO; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY;

AGED; AGED, 80 AND OVER; ANTI-HIV AGENTS; BONE DENSITY; BONE DISEASES; FEMALE; FRACTURES, BONE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK ASSESSMENT;

EID: 77957855493     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/656412     Document Type: Review

References (126)

1. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94(6):646-650.
2. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994; 843:1-129.
3. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312(7041):1254-1259.
4. Foundation NO. Clinician's guide to prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation, 2010.
5. Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS 2003; 17(13):1917-1923.
6. Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS 2001; 15(6):703-709.
7. Dolan SE, Huang JS, Killilea KM, Sullivan MP, Aliabadi N, Grinspoon S. Reduced bone density in HIV-infected women. AIDS 2004; 18(3): 475-483.
8. Knobel H, Guelar A, Vallecillo G, Nogues X, Diez A. Osteopenia in HIV-infected patients: is it the disease or is it the treatment? AIDS 2001; 15(6):807-808.
9. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS 2000; 14(4):F63-F67.
10. Teichmann J, Stephan E, Lange U, et al. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy. J Infect 2003; 46(4):221-227.
11. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007; 21(5):617-623.
12. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Santoro N, Schoenbaum EE. HIV infection and bone mineral density in middle-aged women. Clin Infect Dis 2006; 42(7):1014-1020.
13. Jones S, Restrepo D, Kasowitz A, et al. Risk factors for decreased bone density and effects of HIV on bone in the elderly. Osteoporos Int 2008; 19(7):913-918.
14. Yin M, Dobkin J, Brudney K, et al. Bone mass and mineral metabolism in HIV+ postmenopausal women. Osteoporos Int 2005; 16(11):1345-1352.
15. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS 2006; 20(17): 2165-2174.
16. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr 2009; 51(5):554-561.
17. Cassetti I, Madruga JV, Suleiman JM, et al. The safety and efficacy of tenofovir DF in combination with lamivudine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials 2007; 8(3):164-172. (Pubitemid 47121761)
18. Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. AIDS 2009; 23(7):817-824.
19. Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab 2008; 93(3):861-868.
20. Bolland MJ, Grey AB, Horne AM, et al. Bone mineral density is not reduced in HIV-infected caucasian men treated with highly active antiretroviral therapy. Clin Endocrinol (Oxf) 2006; 65(2):191-197.
21. Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 2006; 91(8):2938-2945.
22. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis 2003; 36(4):482-490.
23. Dao C, Young B, Buchacz K, et al. Higher and increasing rates of fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared to the general US population, 1994 to 2008 [abstract 128]. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections, 18 February 2010, San Francisco, CA.
24. Womack J, Goulet J, Gibert C, et al. HIV-infection and fragility fracture risk among male veterans [abstract 129]. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections, 18 February 2010, San Francisco, CA.
25. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non- HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab 2008; 93(9):3499-3504.
26. Collin F, Duval X, Le Moing V, et al. Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS 2009; 23(8):1021-1024.
27. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292(2):191-201.
28. Overton E, Mondy K, Bush T, et al. Factors associated with low bone mineral density (BMD) in a chort of HIV-Infected U.S. adults - baseline results from the SUN study [abstract 836]. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections, 26 February 2007, Los Angeles, CA.
29. Tebas P, Umbleja T, Dube M. Initiation of ART is associated with bone loos independent of the specific ART regimen: Results of ACTG A5005s [abstract 837]. In: Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, 26 February 2007, Los Angeles, CA.
30. Fakruddin JM, Laurence J. HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol 2005; 150(1):67-78.
31. Borderi M, Gibellini D, Crignis ED, et al. HIV-1 Induces apoptosis in primary osteoblasts: an alternative mechanism in the development of osteopenia and osteoporosis [abstract 759]. In Program and abstracts of the 15th Conference on Retroviruses and Opportunistic Infections, February 2009, Montreal, Canada.
32. Gibellini D, De Crignis E, Ponti C, et al. HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol 2008; 80(9):1507-1514.
33. Bismar H, Diel I, Ziegler R, Pfeilschifter J. Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement. J Clin Endocrinol Metab 1995; 80(11):3351-3355.
34. Guaraldi G, Orlando G, Squillace N, et al. Prevalence of secondary causes of osteoporosis among HIV-infected individuals. In: Program and abstracts of the 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Francisco, CA, 24-26 September 2006.
35. Rodriguez M, Daniels B, Gunawardene S, Robbins GK. High frequency of vitamin D deficiency in ambulatory HIV-Positive patients. AIDS Res Hum Retroviruses 2009; 25(1):9-14.
36. Stephensen CB, Marquis GS, Kruzich LA, Douglas SD, Aldrovandi GM, Wilson CM. Vitamin D status in adolescents and young adults with HIV infection. Am J Clin Nutr 2006; 83(5):1135-1141.
37. Teichmann J, Lange U, Discher T, Lohmeyer J, Stracke H, Bretzel RG. Bone mineral density in human immunodeficiency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART). Eur J Med Res 2009; 14(2):59-64.
38. Rosen CJ, Klibanski A. Bone, fat, and body composition: evolving concepts in the pathogenesis of osteoporosis. Am J Med 2009; 122(5): 409-414.
39. Gilsanz V, Chalfant J, Mo AO, Lee DC, Dorey FJ, Mittelman SD. Reciprocal relations of subcutaneous and visceral fat to bone structure and strength. J Clin Endocrinol Metab 2009; 94(9):3387-3393.
40. Brown TT, Ruppe MD, Kassner R, et al. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab 2004; 89(3):1200-1206.
41. Huang JS, Wilkie SJ, Sullivan MP, Grinspoon S. Reduced bone density in androgen-deficient women with acquired immune deficiency syndrome wasting. J Clin Endocrinol Metab 2001; 86(8):3533-3539.
42. McComsey GA, Kitch D, Daar E, et al. Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded phase III trial of ABC/3TC or TDF/FTC with EFV or ATV/r for initial treatment of HIV-1 infection [abstract 106LB]. In: Program and abstracts of the 17th Conference on Retroviruses and Opportunistic Infections 16-19 February 2010, San Francisco, CA.
43. Madeddu G, Spanu A, Solinas P, et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging 2004; 48(1):39-48.
44. Fernandez-Rivera J, Garcia R, Lozano F, et al. Relationship between low bone mineral density and highly active antiretroviral therapy including protease inhibitors in HIV-infected patients. HIV Clin Trials 2003; 4(5):337-346.
45. Amiel C, Ostertag A, Slama L, et al. BMD is reduced in HIV-infected men irrespective of treatment. J Bone Miner Res 2004; 19(3):402-409.
46. Cozzolino M, Vidal M, Arcidiacono MV, Tebas P, Yarasheski KE, Dusso AS. HIV-protease inhibitors impair vitamin D bioactivation to 1,25-dihydroxyvitamin D. AIDS 2003; 17(4):513-520.
47. Dusso A, Vidal M, Powderly W, Yarashesky K, Tebas P. Protease inhibitors inhibit in vitro conversion of 25[OH]-vitamin D to 1,25[OH]2- vitamin D. Antivir Ther 2000; 5:19.
48. Cooper DA, Bloch M, Humphries A, et al. Simplification with fixed-dose tenofovir-emtricitaine or abacavir-lamivudine in adults with suppressed HIV repliation (The Steal Study): A randomized, open-label, 96-week, non-inferiority trial [abstract 576]. In Program and abstracts of the 16th Conference on Retroviruses and Opportunistic Infections 8-11 February 2009, Montreal, Canada.
49. Stellbrink H, Moyle G, Orkin C, et al. Assessment of safety and efficacy of abacavir/lamivudine and tenofovir/emtricitabine in treatment-naive HIV-1 infected subjects. ASSERT: 48-Week Result. In Program and abstracts of the 12th European AIDS Conference, 11-14 November 2009, Cologne, Germany.
50. Fux CA, Rauch A, Simcock M, et al. Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study. Antivir Ther 2008; 13(8):1077-1082.
51. Ellfolk M, Norlin M, Gyllensten K, Wikvall K. Regulation of human vitamin D(3) 25-hydroxylases in dermal fibroblasts and prostate cancer LNCaP cells. Mol Pharmacol 2009; 75(6):1392-1399.
52. Fabbriciani G, De Socio GV. Efavirenz and bone health. AIDS 2009; 23(9):1181.
53. Herzmann C, Arasteh K. Efavirenz-induced osteomalacia. AIDS 2009; 23(2):274-275.
54. Landriscina M, Altamura SA, Roca L, et al. Reverse transcriptase inhibitors induce cell differentiation and enhance the immunogenic phenotype in human renal clear-cell carcinoma. Int J Cancer 2008; 122(12):2842-2850.
55. Mouly S, Lown KS, Kornhauser D, et al. Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 2002; 72(1):1-9.
56. Mora S, Gilsanz V. Establishment of peak bone mass. Endocrinol Metab Clin North Am 2003; 32(1):39-63.
57. Lewiecki EM, Gordon CM, Baim S, et al. International Society for Clinical Densitometry 2007 adult and pediatric official positions. Bone 2008; 43(6):1115-1121.
58. Webber CE, Sala A, Barr RD. Accounting for body size deviations when reporting bone mineral density variables in children. Osteoporos Int 2009; 20(1):113-121.
59. Gertner JM, Kaufman FR, Donfield SM, et al. Delayed somatic growth and pubertal development in human immunodeficiency virus-infected hemophiliac boys: Hemophilia Growth and Development Study. J Pediatr 1994; 124(6):896-902.
60. Moye J Jr, Rich KC, Kalish LA, et al. Natural history of somatic growth in infants born to women infected by human immunodeficiency virus. Women and Infants Transmission Study Group. J Pediatr 1996; 128(1): 58-69.
61. Wren TA, Kim PS, Janicka A, Sanchez M, Gilsanz V. Timing of peak bone mass: discrepancies between CT and DXA. J Clin Endocrinol Metab 2007; 92(3):938-941.
62. Arpadi S, Horlick M, Shane E. Metabolic bone disease in human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2004; 89(1):21-23.
63. Arpadi SM, Horlick M, Thornton J, Cuff PA, Wang J, Kotler DP. Bone mineral content is lower in prepubertal HIV-infected children. J Acquir Immune Defic Syndr 2002; 29(5):450-454.
64. Jacobson DL, Spiegelman D, Duggan C, et al. Predictors of bone mineral density in human immunodeficiency virus-1 infected children. J Pediatr Gastroenterol Nutr 2005; 41(3):339-346.
65. Mora S, Sala N, Bricalli D, Zuin G, Chiumello G, Vigano A. Bone mineral loss through increased bone turnover in HIV-infected children treated with highly active antiretroviral therapy. AIDS 2001; 15(14):1823-1829.
66. Mora S, Zamproni I, Beccio S, Bianchi R, Giacomet V, Vigano A. Longitudinal changes of bone mineral density and metabolism in antiretroviral-treated human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2004; 89(1):24-28. (Pubitemid 38183854)
67. Mora S, Zamproni I, Giacomet V, Cafarelli L, Figini C, Vigano A. Analysis of bone mineral content in horizontally HIV-infected children naive to antiretroviral treatment. Calcif Tissue Int 2005; 76(5): 336-340.
68. O'Brien KO, Razavi M, Henderson RA, Caballero B, Ellis KJ. Bone mineral content in girls perinatally infected with HIV. Am J Clin Nutr 2001; 73(4):821-826.
69. Pitukcheewanont P, Safani D, Church J, Gilsanz V. Bone measures in HIV-1 infected children and adolescents: disparity between quantitative computed tomography and dual-energy X-ray absorptiometry measurements. Osteoporos Int 2005; 16(11):1393-1396. (Pubitemid 41532092)
70. Purdy JB, Gafni RI, Reynolds JC, Zeichner S, Hazra R. Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus. J Pediatr 2008; 152(4):582-584.
71. Rosso R, Vignolo M, Parodi A, et al. Bone quality in perinatally HIV-infected children: role of age, sex, growth, HIV infection, and antiretroviral therapy. AIDS Res Hum Retroviruses 2005; 21(11):927-932.
72. Soler Palacin P, Torrent A, Rossich R, et al. Osteoporosis and multiple fractures in an antiretroviral-naive, HIV-positive child. J Pediatr Endocrinol Metab 2007; 20(8):933-938.
73. Tan BM, Nelson RP Jr, James-Yarish M, Emmanuel PJ, Schurman SJ. Bone metabolism in children with human immunodeficiency virus infection receiving highly active anti-retroviral therapy including a protease inhibitor. J Pediatr 2001; 139(3):447-451.
74. Vignolo M, Rosso R, Parodi A, Viscoli C. Quantitative ultrasound and bone density in vertically HIV-infected children. Clin Infect Dis 2006; 43(1):112-113; author reply, 3-4.
75. Stagi S, Bindi G, Galluzzi F, Galli L, Salti R, de Martino M. Changed bone status in human immunodeficiency virus type 1 (HIV-1) perinatally infected children is related to low serum free IGF-I. Clin Endocrinol Oxf 2004; 61(6):692-699.
76. Matarazzo P, Palomba E, Lala R, et al. Growth impairment, IGF I hyposecretion and thyroid dysfunction in children with perinatal HIV- 1 infection. Acta Paediatr 1994; 83(10):1029-1034.
77. Hazra R, Gafni RI, Maldarelli F, et al. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Pediatrics 2005; 116(6):e846-e854.
78. Jacobson DL, Lindsey JC, Gordon CM, et al. Total body and spinal bone mineral density across Tanner stage in perinatally HIV-infected and uninfected children and youth in PACTG 1045. AIDS 2010; 24(5): 687-696.
79. Villamor E. A potential role for vitamin D on HIV infection? Nutr Rev 2006; 64(5 Pt 1):226-233.
80. Pettifor JM. Nutritional rickets: deficiency of vitamin D, calcium, or both? Am J Clin Nutr 2004; 80(6 Suppl):1725S-1729S.
81. Puri S, Marwaha RK, Agarwal N, et al. Vitamin D status of apparently healthy schoolgirls from two different socioeconomic strata in Delhi: relation to nutrition and lifestyle. Br J Nutr 2008; 99(4):876-882.
82. Dannhauser A, van Staden AM, van der Ryst E, et al. Nutritional status of HIV-1 seropositive patients in the Free State Province of South Africa: anthropometric and dietary profile. Eur J Clin Nutr 1999; 53(3):165-173.
83. Sachan A, Gupta R, Das V, Agarwal A, Awasthi PK, Bhatia V. High prevalence of vitamin D deficiency among pregnant women and their newborns in northern India. Am J Clin Nutr 2005; 81(5):1060-1064.
84. Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis 2009; 49(5):651-681.
85. Johnell O, Kanis JA, Black DM, et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J Bone Miner Res 2004; 19(5): 764-772.
86. McComsey GA, Huang JS, Woolley IJ, et al. Fragility fractures in HIV-infected patients: need for better understanding of diagnosis and management. J Int Assoc Physicians AIDS Care Chic Ill 2004; 3(3):86-91.
87. Tannenbaum C, Clark J, Schwartzman K, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2002; 87(10):4431-4437.
88. Cohen A, Fleischer J, Freeby MJ, McMahon DJ, Irani D, Shane E. Clinical characteristics and medication use among premenopausal women with osteoporosis and low BMD: the experience of an osteoporosis referral center. J Womens Health Larchmt 2009; 18(1):79-84.
89. Cohen A, Shane E. Primer on the metabolic bone diseases and other disorders of bone and mineral metbolism: premenopausal osteoporosis. 7th ed. Rosen C, ed. New York: JW Wiley, 2008.
90. Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev 2008; 29(4):441-464.
91. Bolland MJ, Grey AB, Gamble GD, Reid IR. CLINICAL review: low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab 2007; 92(12):4522-4528.
92. Chew NS, Doran PP, Powderly WG. Osteopenia and osteoporosis in HIV: pathogenesis and treatment. Curr Opin HIV AIDS 2007; 2(4): 318-323.
93. Pollock E, Klotsas AE, Compston J, Gkrania-Klotsas E. Bone health in HIV infection. Br Med Bull 2009; 92:123-133.
94. Kanis J, Johnell O, Gullberg B, et al. Risk factors for hip fracture in men from southern Europe: the MEDOS study. Mediterranean Osteoporosis Study. Osteoporos Int 1999; 9(1):45-54.
95. Melton LJ 3rd, Atkinson EJ, Khosla S, O'Fallon WM, Riggs BL. Secondary osteoporosis and the risk of vertebral deformities in women. Bone 1999; 24(1):49-55.
96. Poor G, Atkinson EJ, O'Fallon WM, Melton LJ 3rd. Predictors of hip fractures in elderly men. J Bone Miner Res 1995; 10(12):1900-1907.
97. FRAX WHO Fracture Risk Assessment Tool. University of Sheffield, UK. http://www.shef.ac.uk/FRAX/. Accessed 7 September 2010.
98. Lundgren JD, Battegay M, Behrens G, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med 2008; 9(2):72-81.
99. Gregg EW, Cauley JA, Seeley DG, Ensrud KE, Bauer DC. Physical activity and osteoporotic fracture risk in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1998; 129(2): 81-88.
100. Rosen H, Drezner M. Overview of the management of osteoporosis in women. In: Rose B, ed. Wellsley, MA: UpToDate Online 18.2, 2010. http://www. uptodateonline.com.
101. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004; 89(11): 5387-5391.
102. Romagnoli E, Mascia ML, Cipriani C, et al. Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J Clin Endocrinol Metab 2008; 93(8):3015-3020.
103. Cannell JJ, Hollis BW, Zasloff M, Heaney RP. Diagnosis and treatment of vitamin D deficiency. Expert Opin Pharmacother 2008; 9(1):107-118.
104. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357(3):266-281.
105. Sanders KM, Stuart AL, Williamson EJ, et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010; 303(18):1815-1822.
106. Vieth R. Critique of the considerations for establishing the tolerable upper intake level for vitamin D: critical need for revision upwards. J Nutr 2006; 136(4):1117-1122.
107. Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K. Bisphosphonate- induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract 2006; 12(1):48-53.
108. Adami S, Giannini S, Bianchi G, et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int 2009; 20(2):239-244.
109. Bilezikian JP. Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis. Am J Med 2009; 122(2 Suppl):S14-S21.
110. McComsey GA, Kendall MA, Tebas P, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS 2007; 21(18):2473-2482.
111. Mondy K, Powderly WG, Claxton SA, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr 2005; 38(4):426-431.
112. Bolland MJ, Grey AB, Horne AM, et al. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab 2007; 92(4):1283-1288.
113. Huang J, Meixner L, Fernandez S, McCutchan JA. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS 2009; 23(1):51-57.
114. Miller PD. Is there a role for bisphosphonates in chronic kidney disease? Semin Dial 2007; 20(3):186-190.
115. Khan AA, Sandor GK, Dore E, et al. Bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2009; 36(3):478-490.
116. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22(10):1479-1491.
117. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356(18):1809-1822.
118. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009; 360(1):89-90.
119. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90(3):1294-1301.
120. Lenart BA, Neviaser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 2009; 20(8):1353-1362.
121. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350(12):1189-1199.
122. Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010; 362(19):1761-1771.
123. Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab 2005; 90(3):1897-1899.
124. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 2003; 349(13):1216-1226.
125. Rosen HN, Moses AC, Garber J, Ross DS, Lee SL, Greenspan SL. Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. Calcif Tissue Int 1998; 63(5): 363-368.
126. Dolin R, Masur H, Saag M. Bone disorders. 3rd ed. Livingstone C, editor. Philadelphia, PA: Elsevier; 2008.